Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (GB:0HF9)
LSE:0HF9
Amicus (0HF9) Stock Price & Analysis
0 Followers
0HF9 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.14 - $13.73
Previous Close$10.81
Volume88.00
Average Volume (3M)1.36K
Market Cap
$3.17B
Enterprise Value$3.24B
Total Cash (Recent Filing)$293.60M
Total Debt (Recent Filing)$452.12M
Price to Earnings (P/E)N/A
Beta0.93
Next Earnings
May 08, 2023EPS Estimate
-$0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding282,714,738
10 Day Avg. Volume661
30 Day Avg. Volume1,359
Standard Deviation0.16
R-Squared0.13
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-32.13
Price to Sales (P/S)16.50
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-18.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.85
Enterprise Value/Gross Profit11.16
Enterprise Value/Ebitda-16.25
Forecast
1Y Price Target
$15.00Price Target Upside38.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Amicus News
0HF9 FAQ
What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest stock price was $6.14 and its highest was $13.72 in the past 12 months.
What is Amicus Therapeutics’s market cap?
Currently, no data Available
When is Amicus Therapeutics’s upcoming earnings report date?
Amicus Therapeutics’s upcoming earnings report date is May 08, 2023 which is in 37 days.
How were Amicus Therapeutics’s earnings last quarter?
Amicus Therapeutics released its earnings results on Mar 01, 2023. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.117 by -$0.073.
Is Amicus Therapeutics overvalued?
According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued.
Does Amicus Therapeutics pay dividends?
Amicus Therapeutics does not currently pay dividends.
What is Amicus Therapeutics’s EPS estimate?
Amicus Therapeutics’s EPS estimate is -$0.14.
How many shares outstanding does Amicus Therapeutics have?
Currently, no data Available
What happened to Amicus Therapeutics’s price movement after its last earnings report?
Amicus Therapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.117. Following the earnings report the stock price went up 3.179%.
Which hedge fund is a major shareholder of Amicus Therapeutics?
Among the largest hedge funds holding Amicus Therapeutics’s share is Perceptive Advisors LLC. It holds Amicus Therapeutics’s shares valued at 338M.
---
Amicus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (38.75% Upside)
$15.00 (38.75% Upside)
Blogger Sentiment
Bullish
GB:0HF9 Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Positive
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.49%
12-Months-Change
Fundamentals
Return on Equity
-109.93%
Trailing 12-Months
Asset Growth
-19.99%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Amicus Therapeutics
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
---
Intellia Therapeutics
―
Vir Biotechnology
―
Vaxcyte
―
Amicus
―
Arrowhead Pharmaceuticals
―
---